SCHEMBL17879374

SCHEMBL17879374

Cc1ccc(C(c2ccc(C)cc2)c2ccc(C=Cc3ccc(C=Cc4ccc(N(c5ccc(C)cc5)c5ccc(C)cc5)cc4)cc3)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 4/20 0.45
RELA Q04206 2/20 0.42
ALOX5 P09917 1/20 0.40
PTGS1 P23219 1/20 0.40
PTGS2 P35354 1/20 0.40
MEN1 O00255 2/20 0.39
APOBEC3A P31941 2/20 0.39
RAB9A P51151 2/20 0.39
KMT2A Q03164 2/20 0.39
APOBEC3G Q9HC16 2/20 0.39
CA1 P00915 1/20 0.38
NPC1 O15118 1/20 0.38
GAA P10253 1/20 0.38
GFER P55789 1/20 0.38
CHRNA7 P36544 1/20 0.38
APP P05067 3/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
TUBB4A P04350 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12120252 1.00 NFE2L2 (0.45) NFE2L2RELAALOX5PTGS1PTGS2
SCHEMBL13807903 1.00 NFE2L2 (0.45) NFE2L2RELAALOX5PTGS1PTGS2
SCHEMBL18198856 1.00 NFE2L2 (0.45) NFE2L2RELAALOX5PTGS1PTGS2
SCHEMBL13308456 0.90 NFE2L2 (0.50) NFE2L2RELAALOX5PTGS1PTGS2
SCHEMBL13308475 0.89 PTGS1 (0.40) NFE2L2RELAALOX5PTGS1PTGS2
SCHEMBL16489726 0.88 NFE2L2 (0.56) NFE2L2RELAALOX5PTGS1PTGS2
SCHEMBL3629423 0.88 NFE2L2 (0.56) NFE2L2RELAALOX5PTGS1PTGS2
SCHEMBL10015739 0.88 NFE2L2 (0.56) NFE2L2RELAALOX5PTGS1PTGS2
SCHEMBL6764358 0.88 CHRNA7 (0.46) ALOX5MEN1KMT2ACA1GAA
SCHEMBL20663990 0.88 NFE2L2 (0.56) NFE2L2RELAALOX5PTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10862047-B2 Organic electroluminescent device KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2020-12-08 US disclosed
US-10658596-B2 2020-05-19 US disclosed
US-10381573-B2 Light-emitting material, organic light-emitting device, and compound KYULUX, INC. (JP) 2019-08-13 US disclosed
US-20160380205-A1 LIGHT-EMITTING MATERIAL, ORGANIC LIGHT-EMITTING DEVICE, AND COMPOUND KYULUX, INC. (JP) 2016-12-29 US disclosed
US-20160190478-A1 ORGANIC ELECTROLUMINESCENT DEVICE KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2016-06-30 US disclosed
US-20160190478-A1 ORGANIC ELECTROLUMINESCENT DEVICE KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2016-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10381573-B2 Light-emitting material, organic light-emitting device, and compound CRY1, CRY2, GLB1 NFE2L2 386/4885RELA 747/4885ALOX5 2406/4885
US-20160380205-A1 LIGHT-EMITTING MATERIAL, ORGANIC LIGHT-EMITTING DEVICE, AND COMPOUND CRY1, CRY2, GLB1 NFE2L2 346/4885RELA 776/4885ALOX5 2251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.